Exane Derivatives’s Raytheon Company RTN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-6
Closed -$787 757
2020
Q1
$787 Sell
6
-39
-87% -$7.72K ﹤0.01% 556
2019
Q4
$10.3K Sell
45
-1,059
-96% -$224K ﹤0.01% 413
2019
Q3
$217K Sell
1,104
-5,912
-84% -$1.1M 0.04% 243
2019
Q2
$1.22M Buy
7,016
+5,728
+445% +$1.03M 0.21% 95
2019
Q1
$234K Sell
1,288
-4,843
-79% -$844K 0.05% 206
2018
Q4
$940K Sell
6,131
-15,613
-72% -$2.8M 0.17% 126
2018
Q3
$4.49M Buy
21,744
+15,967
+276% +$3.18M 0.84% 22
2018
Q2
$1.12M Buy
+5,777
New +$1.21M 0.19% 118
2017
Q4
Sell
-1
Closed -$187 648
2017
Q3
$187 Sell
1
-3
-75% -$528 ﹤0.01% 491
2017
Q2
$646 Buy
+4
New +$634 ﹤0.01% 492
2016
Q2
Sell
-480
Closed -$58.9K 640
2016
Q1
$58.9K Sell
480
-427
-47% -$52.6K 0.01% 285
2015
Q4
$113K Buy
+907
New +$109K 0.02% 194
2015
Q3
Sell
-225,989
Closed -$21.6M 577
2015
Q2
$21.6M Buy
+225,989
New +$23.7M 2.33% 24

Other funds holding RTN

Exane Derivatives's RTN Position: Q2 2020 in Review

Exane Derivatives sold out of Raytheon Company (RTN) in Q2 2020, closing a stake of 6 shares — an estimated $787 sold.

Exane Derivatives first reported a position in RTN in Q2 2015 and held it in 13 quarters. The position peaked at $21.6M in Q2 2015. 75 funds tracked by Wall St. Rank hold RTN as of Q2 2020.

  • Exane Derivatives reported no remaining Raytheon Company position as of Q2 2020 after selling out during the quarter.
  • Exane Derivatives sold 6 Raytheon Company shares in Q2 2020, an estimated $787.
  • Exane Derivatives first reported a position in Raytheon Company in Q2 2015 and held it in 13 quarters.
  • Exane Derivatives's Raytheon Company position peaked at $21.6M in Q2 2015.
  • 75 funds tracked by Wall St. Rank held Raytheon Company as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.